$5.29
1.34% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US56600D1072
Symbol
MRVI

Maravai LifeSciences Stock price

$5.29
-1.73 24.64% 1M
-5.56 51.24% 6M
-1.26 19.24% YTD
+0.17 3.32% 1Y
-31.87 85.76% 3Y
-24.56 82.28% 5Y
-24.56 82.28% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.07 1.34%
ISIN
US56600D1072
Symbol
MRVI
Sector
Industry

Key metrics

Market capitalization $750.35m
Enterprise Value $1.00b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.62
P/S ratio (TTM) P/S ratio 2.71
P/B ratio (TTM) P/B ratio 2.17
Revenue growth (TTM) Revenue growth -33.99%
Revenue (TTM) Revenue $276.92m
EBIT (operating result TTM) EBIT $-41.15m
Free Cash Flow (TTM) Free Cash Flow $-10.72m
Cash position $578.16m
EPS (TTM) EPS $-1.65
P/E forward negative
P/S forward 2.89
EV/Sales forward 3.86
Short interest 6.93%
Show more

Is Maravai LifeSciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Maravai LifeSciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Maravai LifeSciences forecast:

8x Buy
57%
6x Hold
43%

Analyst Opinions

14 Analysts have issued a Maravai LifeSciences forecast:

Buy
57%
Hold
43%

Financial data from Maravai LifeSciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
277 277
34% 34%
100%
- Direct Costs 170 170
0% 0%
61%
107 107
57% 57%
39%
- Selling and Administrative Expenses 74 74
11% 11%
27%
- Research and Development Expense 19 19
9% 9%
7%
14 14
91% 91%
5%
- Depreciation and Amortization 55 55
26% 26%
20%
EBIT (Operating Income) EBIT -41 -41
139% 139%
-15%
Net Profit -225 -225
1,015% 1,015%
-81%

In millions USD.

Don't miss a Thing! We will send you all news about Maravai LifeSciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Maravai LifeSciences Stock News

Neutral
GlobeNewsWire
14 days ago
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November.
Neutral
Seeking Alpha
17 days ago
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Deb Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - EVP and Chief Financial Officer Drew Burch - President, Nucleic Acid Production Conference Call Participants Dan Leonard - UBS Justin Bowers - Deutsche Bank Yuko Oku - Morgan S...
Neutral
Business Wire
19 days ago
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research.
More Maravai LifeSciences News

Company Profile

Maravai Lifesciences Holdings, Inc. operates as an investment holding company. It develops biopharmaceuticals. The company is headquartered in San Diego, CA.

Head office United States
CEO William Martin
Employees 650
Founded 2014
Website www.maravai.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today